This study aimed to comprehensively evaluate the biological activity in different passage populations of mesenchymal stem cells (BMSCs) derived from bone marrow in ovariectomy osteoporotic rats (named OVX-rBMSCs), providing experimental basis for new osteoporotic drug development and research. OVX-rBMSCs were isolated and cultured in vitro by the whole bone marrow adherent screening method. The morphological observation, cell surface markers (CD29, CD45, CD90) detection, cell proliferation, induced differentiation experimental detection were performed to evaluate the biological activity of Passage 1, 2, 3, 4 populations (P1, P2, P3, P4) OVX-rBMSCs. The results showed that whole bone marrow adherent culture method isolated and differentially subcultured OVX-The morphology of P4 OVX-rBMSCs was identical fibroblast-like and had the characteristics of ultrastructure of stem cells. The CD29 positive cells rate, CD90 positive cells rate, cell proliferation index, and the osteogenic, adipogenic, chondrogenic differentiation capacities of P4 OVX-rBMSCs were significantly better than those of other populations (P < 0.05). OVX-rBMSCs purity and biological activity were gradually optimized with the passaged, and among them P4 cells were superior to all the other populations. Based on these results, we report that the P4 OVX-rBMSCs model developed in this study can be used to develop a new and effective medical method for osteoporotic drug screening.
Citation：
WANG Yanyan, LING Bin, ZHAO Zhijie, LU Xing, LUO Li, GONG Zhongcheng, ZHAO Chunmei, WU Jiang. Comprehensive Evaluation of Biological Activity in Different Passage Populations of Mesenchymal Stem Cells Derived from Bone Marrow in Ovariectomy Osteoporotic Rats. Journal of Biomedical Engineering, 2016, 33(5): 916-922. doi: 10.7507/1001-5515.20160148
Copy
Copyright © the editorial department of Journal of Biomedical Engineering of West China Medical Publisher. All rights reserved
| 1. |
LIN Xiao, XIONG Dan, PENG Yiqun, et al. Epidemiology and management of osteoporosis in the People's Republic of China:current perspectives[J]. Clin Interv Aging, 2015, 10:1017-1033.
|
| 2. |
WANG O, HU Y, GONG S, et al. A survey of outcomes and management of patients post fragility fractures in China[J]. Osteoporos Int, 2015, 26(11):2631-2640.
|
| 3. |
VILLA J C, GIANAKOS A, LANE J M. Bisphosphonate treatment in osteoporosis:optimal duration of therapy and the incorporation of a drug holiday[J]. HSS J, 2016, 12(1):66-73.
|
| 4. |
LINDSAY R, KREGE J H, MARIN F, et al. Teriparatide for osteoporosis:importance of the full course[J]. Osteoporos Int, 2016, 27(8):2395-2410.
|
| 5. |
YAO X L, LI L, HE X L, et al. Activation of β-catenin stimulated by mechanical strain and estrogen requires estrogen receptor in mesenchymal stem cells (MSCs)[J]. Eur Rev Med Pharmacol Sci, 2014, 18(21):3149-3155.
|
| 6. |
GENNARI L, ROTATORI S, BIANCIARDI S, et al. Appropriate models for novel osteoporosis drug discovery and future perspectives[J]. Expert Opin Drug Discov, 2015, 10(11):1201-1216.
|
| 7. |
吕鑫. SPIO标记大鼠骨髓间充质干细胞:生物学活性及体外MRI成像效应评价[D].乌鲁木齐:新疆医科大学, 2014.
|
| 8. |
BLACK D M, ROSEN C J. Clinical practice. postmenopausal osteoporosis[J]. N Engl J Med, 2016, 374(3):254-262.
|
| 9. |
MCCLUNG M R. Emerging therapies for osteoporosis[J]. Endocrinol Metab (Seoul), 2015, 30(4):429-35.
|
| 10. |
JEPSEN K J, SCHLECHT S H, KOZLOFF K M. Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?[J]. Curr Opin Pharmacol, 2014, 16:64-71.
|
| 11. |
ITO H. Clinical considerations of regenerative medicine in osteoporosis[J]. Curr Osteoporos Rep, 2014, 12(2):230-234.
|
| 12. |
CAI Yiting, LIU Tianshu, FANG Fang, et al. Comparisons of mouse mesenchymal stem cells in primary adherent culture of compact bone fragments and whole bone marrow[J]. Stem Cells Int, 2015, 2015:708906.
|
| 13. |
ZHANG Weidong, ZHANG Fangbiao, SHI Hongcan, et al. Comparisons of rabbit bone marrow mesenchymal stem cell isolation and culture methods in vitro[J]. PLoS One, 2014, 9(2):e88794.
|
- 1. LIN Xiao, XIONG Dan, PENG Yiqun, et al. Epidemiology and management of osteoporosis in the People's Republic of China:current perspectives[J]. Clin Interv Aging, 2015, 10:1017-1033.
- 2. WANG O, HU Y, GONG S, et al. A survey of outcomes and management of patients post fragility fractures in China[J]. Osteoporos Int, 2015, 26(11):2631-2640.
- 3. VILLA J C, GIANAKOS A, LANE J M. Bisphosphonate treatment in osteoporosis:optimal duration of therapy and the incorporation of a drug holiday[J]. HSS J, 2016, 12(1):66-73.
- 4. LINDSAY R, KREGE J H, MARIN F, et al. Teriparatide for osteoporosis:importance of the full course[J]. Osteoporos Int, 2016, 27(8):2395-2410.
- 5. YAO X L, LI L, HE X L, et al. Activation of β-catenin stimulated by mechanical strain and estrogen requires estrogen receptor in mesenchymal stem cells (MSCs)[J]. Eur Rev Med Pharmacol Sci, 2014, 18(21):3149-3155.
- 6. GENNARI L, ROTATORI S, BIANCIARDI S, et al. Appropriate models for novel osteoporosis drug discovery and future perspectives[J]. Expert Opin Drug Discov, 2015, 10(11):1201-1216.
- 7. 吕鑫. SPIO标记大鼠骨髓间充质干细胞:生物学活性及体外MRI成像效应评价[D].乌鲁木齐:新疆医科大学, 2014.
- 8. BLACK D M, ROSEN C J. Clinical practice. postmenopausal osteoporosis[J]. N Engl J Med, 2016, 374(3):254-262.
- 9. MCCLUNG M R. Emerging therapies for osteoporosis[J]. Endocrinol Metab (Seoul), 2015, 30(4):429-35.
- 10. JEPSEN K J, SCHLECHT S H, KOZLOFF K M. Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?[J]. Curr Opin Pharmacol, 2014, 16:64-71.
- 11. ITO H. Clinical considerations of regenerative medicine in osteoporosis[J]. Curr Osteoporos Rep, 2014, 12(2):230-234.
- 12. CAI Yiting, LIU Tianshu, FANG Fang, et al. Comparisons of mouse mesenchymal stem cells in primary adherent culture of compact bone fragments and whole bone marrow[J]. Stem Cells Int, 2015, 2015:708906.
- 13. ZHANG Weidong, ZHANG Fangbiao, SHI Hongcan, et al. Comparisons of rabbit bone marrow mesenchymal stem cell isolation and culture methods in vitro[J]. PLoS One, 2014, 9(2):e88794.
